Cargando…

Philadelphia Chromosome‐positive Chronic Myelogenous Leukemia with Deleted Fusion of BCR and ABL Genes

In the great majority of patients with chronic myelogenous leukemia (CML) the reciprocal translocation between chromosomes 9 and 22, t(9;22)(q34;q11), resulting in the Philadelphia (Ph) chromosome produces fusion DNA sequences consisting of the 5′ part of the major breakpoint cluster region‐1 (M‐BCR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ohyashiki, Kazuma, Ohyashiki, Junko H., Iwabuchi, Hirotaka, Tauchi, Tetsuzo, Iwabuchi, Atsuhiro, Toyama, Keisuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 1990
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917958/ https://www.ncbi.nlm.nih.gov/pubmed/2157692 http://dx.doi.org/10.1111/j.1349-7006.1990.tb02504.x

Ejemplares similares

Therapeutic targeting of Aurora A kinase in Philadelphia chromosome-positive ABL tyrosine kinase inhibitor-resistant cells
por: Okabe, Seiichi, et al.
Publicado: (2018)

Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells
por: Okabe, Seiichi, et al.
Publicado: (2016)

Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells
por: Okabe, Seiichi, et al.
Publicado: (2013)

Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells
por: Okabe, Seiichi, et al.
Publicado: (2014)

Anti-leukemic activity of axitinib against cells harboring the BCR-ABL T315I point mutation
por: Okabe, Seiichi, et al.
Publicado: (2015)

Combining the ABL1 Kinase Inhibitor Ponatinib and the Histone Deacetylase Inhibitor Vorinostat: A Potential Treatment for BCR-ABL-Positive Leukemia
por: Okabe, Seiichi, et al.
Publicado: (2014)

The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population
por: Ohyashiki, Junko H, et al.
Publicado: (2012)

MORPHOLOGIC CHANGES OF NEUTROPHILS IN MYELODYSPLASTIC SYNDROME TREATED WITH RECOMBINANT HUMAN GRANULOCYTE COLONY‐STIMULATING FACTOR
por: Toyama, Keisuke, et al.
Publicado: (1988)

Non‐radioisotopic and Semi‐quantitative Procedure for Terminal Repeat Amplification Protocol
por: Ohyashiki, Junko H., et al.
Publicado: (1996)

Hematologic and Cytogenetic Findings in Myelodysplastic Syndromes Treated with Recombinant Human Granulocyte Colony‐stimulating Factor
por: Ohyashiki, Kazuma, et al.
Publicado: (1989)

Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line
por: Okabe, Seiichi, et al.
Publicado: (2011)

Quantification of BCR-ABL mRNA in Plasma/Serum of Patients with Chronic Myelogenous Leukemia
por: Narita, Miwako, et al.
Publicado: (2012)

Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib
por: Ohyashiki, Kazuma, et al.
Publicado: (2016)

Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse
por: Yoshimoto, Takayuki, et al.
Publicado: (2014)

Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cells
por: Okabe, Seiichi, et al.
Publicado: (2015)

The Functional Interplay Between the t(9;22)-Associated Fusion Proteins BCR/ABL and ABL/BCR in Philadelphia Chromosome-Positive Acute Lymphatic Leukemia
por: Rafiei, Anahita, et al.
Publicado: (2015)

Low body weight and body mass index may be associated with musculoskeletal pain following imatinib discontinuation in chronic myeloid leukemia
por: Katagiri, Seiichiro, et al.
Publicado: (2017)

Association of HLA antigens and BCR-ABL transcripts in leukemia patients with the Philadelphia chromosome
por: de Carvalho, Daiana Landenberger, et al.
Publicado: (2012)

BCR‐ABL exon 7 deletion and novel point mutation in patient with chronic myelogenous leukemia
Publicado: (2019)

Re-evaluating the role of BCR/ABL in chronic myelogenous leukemia
por: Ross, Theodora S, et al.
Publicado: (2014)

The e1a3 BCR-ABL1 Fusion Transcript in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
por: Langabeer, Stephen E.
Publicado: (2015)

Variant BCR-ABL1 fusion genes in adult Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia
por: Langabeer, Stephen E.
Publicado: (2017)

Philadelphia Chromosome-positive Acute Myeloid Leukemia With e1a3 BCR-ABL1 Fusion Transcript
por: Sheets, Julia W., et al.
Publicado: (2020)

Age-related decrease of miRNA-92a levels in human CD8(+ )T-cells correlates with a reduction of naïve T lymphocytes
por: Ohyashiki, Michiyo, et al.
Publicado: (2011)

RUNX1 transactivates BCR‐ABL1 expression in Philadelphia chromosome positive acute lymphoblastic leukemia
por: Masuda, Tatsuya, et al.
Publicado: (2021)

A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia
por: Seymour, J F, et al.
Publicado: (2014)

BCR‐ABL exon 7 deletion and novel point mutation in patient with chronic myelogenous leukemia and TKI resistance
por: Mikhailov, Ilya
Publicado: (2018)

A Case with Coexistence of Major and Minor BCR/ABL Fusion Transcript at Lymphoblastic Crisis of Chronic Myelogenous Leukemia in Patients with Major BCR/ABL Positivity during Chronic Phase
por: Park, Sang Hyuk, et al.
Publicado: (2013)

Multiple copies of BCR-ABL fusion gene on two isodicentric Philadelphia chromosomes in an imatinib mesylate-resistant chronic myeloid leukemia patient
por: AL-ACHKAR, WALID, et al.
Publicado: (2013)

Differences in structural elements of Bcr-Abl oncoprotein isoforms in Chronic Myelogenous Leukemia
por: Hai, Abdul, et al.
Publicado: (2014)

The structural basis of BCR-ABL recruitment of GRB2 in chronic myelogenous leukemia
por: Liu, Yonglan, et al.
Publicado: (2022)

A network biology approach evaluating the anticancer effects of bortezomib identifies SPARC as a therapeutic target in adult T-cell leukemia cells
por: Ohyashiki, Junko H, et al.
Publicado: (2008)

FISH mapping of Philadelphia negative BCR/ABL1 positive CML
por: Virgili, Anna, et al.
Publicado: (2008)

Hypoxia-induced paclitaxel resistance in cervical cancer modulated by miR-100 targeting of USP15
por: Nishi, Hirotaka, et al.
Publicado: (2023)

Molecular Monitoring in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with the Variant e13a3 BCR-ABL1 Fusion
por: Crampe, Mireille, et al.
Publicado: (2019)

Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia
por: Mukherjee, Kaushiki, et al.
Publicado: (2017)

BCR-ABL Gene Transcript Types of Patients with Chronic Myelogenous Leukemia in Yogyakarta, Indonesia
por: Paramita, Dewi Kartikawati, et al.
Publicado: (2020)

Critical Requirement of SOS1 for Development of BCR/ABL-Driven Chronic Myelogenous Leukemia
por: Gómez, Carmela, et al.
Publicado: (2022)

Chromatin Regulation by HP1γ Contributes to Survival of 5-Azacytidine-Resistant Cells
por: Imanishi, Satoshi, et al.
Publicado: (2018)

Effect of the extracellular component of bone marrow mesenchymal stromal cells from healthy donors on hematologic neoplasms and their angiogenesis
por: Gladkova, Nina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_v8p2mgmkhn8bmgggckhk16c4us